| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10469409 | Journal of Psychosomatic Research | 2014 | 7 Pages |
Abstract
The exclusion of patients with pre-existing cognitive impairment hampers the generalizability of the results of these trials and leaves clinicians with limited evidence about the pharmacological treatment of this group of vulnerable patients who have an increased risk of side effects.
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Annemarieke de Jonghe, Esther M.M. van de Glind, Barbara C. van Munster, Sophia E. de Rooij,